Publication

Mesenchymal Stem Cell and Secretome Treatments Inhibit the mTOR-NOX4 Pathway in Diabetic Kidney Disease.

Citations
Altmetric:
Video URL
Date
2026-03-11
Author
Njeim, Rachel, Alkhansa, Sahar, Almoussawi, Sarah, Slika, Amani, Hamade, Sarah, Al Danaf, Ghaith, Dia, Batoul, Lawandos, Leonard, Eid, Ali H, Kassouf, Hala Kfoury, Harb, Frederic, Fayad, Antoine Abou, Ziyadeh, Fuad N, Khuri, Fadlo R, Eid, Assaad A
Collections
Medicine Research
Show all metadata
Abstract
Despite advances in diabetes management, diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease. We investigated whether mesenchymal stem cells (MSCs) and their conditioned medium, containing the MSC-derived secretome, protect against DKD by modulating the mammalian target of rapamycin (mTOR)/NADPH oxidase (NOX) pathway. MSCs and MSCs-conditioned medium both reduced kidney injury, podocyte structural integrity, oxidative stress, and inflammation by inhibiting mTORC1/mTORC2 and NOX4. MSCs-conditioned medium offers a safe, secretome-based, cell-free approach for DKD therapy.
URI
http://hdl.handle.net/10576/71022